Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin
Date:10/11/2007

- Conference call to be hosted today at 8:30 a.m. Eastern Time -

BRANFORD, Conn., Oct. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II dose-confirmatory clinical trial (CLN-12) evaluating a single dose of velafermin for the prevention of severe oral mucositis demonstrated that velafermin was safe and well-tolerated but did not meet its primary endpoint. Based on these results, the Company is discontinuing the development of velafermin, and will continue to focus its resources on belinostat, a Phase II histone deacetylase (HDAC) inhibitor for the treatment of solid tumors and hematologic malignancies, and CR011-vcMMAE, a Phase I/II antibody-drug conjugate for the treatment of metastatic melanoma.

"While we are disappointed that the primary endpoint was not met in this study, on behalf of everyone at CuraGen, I would like to thank all of the patients and investigators who took part in the velafermin development program," commented Timothy Shannon, President and Chief Executive Officer of CuraGen. "We continue to aggressively focus on our goal of advancing the belinostat and CR011-vcMMAE programs toward initiation of Phase III development in 2008, and we look forward to presenting updated clinical trial results on these programs in October at the AACR-NCI-EORTC conference, and in December at the ASH Annual Meeting."

CLN-12 was a randomized, double-blind, placebo-controlled study designed to assess a reduction in the incidence of severe Grade 3 or 4 oral mucositis in patients receiving high-dose chemotherapy followed by autologous bone marrow transplantation (BMT). The trial enrolled 390
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
(Date:11/21/2014)... 2014  The acceptance of two abstracts on ... Congress demonstrates continued interest in the Eclipse System, ... control. One of the abstracts, presented by Catherine ... of Urogynecology and Reconstructive Pelvic Surgery at the ... Best Written Abstract on Urogynecology/Pelvic Floor Disorders/Vaginal Surgery. ...
(Date:11/21/2014)... 20, 2014   Wellcentive , the industry ... healthcare organizations, announced today being named one of ... Innovation Award .  Sponsored by Intel, the world ... fourth year, recognizes companies developing leading-edge technology and ... processes. Wellcentive,s Mason Beard ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
(Date:11/21/2014)... Recently, TideStore.com, a leading online store offering many ... offer TideStore Thanksgiving Sales . According to the ... provided with big discounts. The special offer is valid ... extra 10% discount with this coupon code: thanks. , ... opportunities to win free gifts. TideStore.com has done much ...
(Date:11/21/2014)... CARE Surrogacy Center in Mexico is ... at the same time enhancing their surrogacy journey with high ... parents across the globe, the company is reporting on its ... zoning in on the skyrocketing costs of surrogacy — and ... over-stressing clinical success rates ? , Fertility clinics ...
(Date:11/21/2014)... TX (PRWEB) November 21, 2014 ... facility at 7am today. The new facility is located ... open 24-7. , “We are pleased to join ... highest quality emergency medical care here,” said Dr. Siddiqi, ... , To celebrate the opening, First Choice ...
(Date:11/21/2014)... Maureen Salamon HealthDay Reporter ... Jobs requiring intellectually challenging tasks may help preserve thinking ... suggests. The researchers compared IQ scores obtained ... with their memory and reasoning scores around age 70. ... jobs appeared to retain sharper thinking even years after ...
(Date:11/21/2014)... (HealthDay News) -- Some people with cochlear implants experience ... when they undergo an MRI scan, a new study ... researchers, about 300,000 people worldwide have cochlear implants, devices ... are deaf or have severe hearing loss. There have ... implants when undergoing MRI. One expert said the ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Sales from TideStore.com 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:First Choice Emergency Room Opens New Facility in Friendswood, Texas 2Health News:Could Your Job Help Preserve Your Aging Brain? 2Health News:Could Your Job Help Preserve Your Aging Brain? 3Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2
... brain, study suggests , , WEDNESDAY, Aug. 22 (HealthDay News) ... traumatic memories go so deep and linger so long ... shows that a powerful neurochemical called norepinephrine is released ... it also "imprints" an emotional fear tagged to the ...
... it prevented buildup of dangerous tau protein , , TUESDAY, ... combat a protein implicated in Alzheimer,s disease has proven ... protein accumulates into damaging tangles in the memory center ... at the New York University Medical Center (NYUMC). , ...
... , TUESDAY, Aug. 21 (HealthDay News) -- Claims of male-female ... or validation, experts report in the Aug. 22/29 issue of ... A team of researchers in Greece analyzed 77 studies that ... percent) of these claims were decided in advance of the ...
... three-quarters of cases went unnoticed, study found , , TUESDAY, ... one in four children who had high blood pressure ... the dangerous problem is missed. , "Hypertension in children ... a pediatrician, internist and fellow at the Center for ...
... major study finds , , TUESDAY, Aug. 21 (HealthDay News) -- ... cancer and acrylamide, a substance found in many baked and ... subject conducted to date. , "The data are accumulating, and ... to be an important breast cancer risk factor," said study ...
... the behavioral and academic problems associated with Attention Deficit ... by researchers at Lehigh Universitys College of Education. , ... National Institute of Mental Health (NIMH), was the largest ... 5 who have shown significant symptoms of ADHD. It ...
Cached Medicine News:Health News:Study Probes Roots of Fearful Memories 2Health News:Gene Studies of Male-Female Differences Often Flawed 2Health News:Doctors Often Miss High Blood Pressure in Kids 2Health News:Doctors Often Miss High Blood Pressure in Kids 3Health News:Acrylamide Won't Raise Breast Cancer Risk 2Health News:Acrylamide Won't Raise Breast Cancer Risk 3Health News:Acrylamide Won't Raise Breast Cancer Risk 4Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 2Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: